The GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro, are causing a concerning issue: a resurgence of a sailors' disease known as scurvy. This is due to the lack of dietary oversight in global trials, leading to patients being functionally malnourished and developing serious vitamin deficiencies. While these drugs are effective for weight loss and diabetes management, their appetite-suppressing nature can be unsustainable if not paired with proper dietary guidance. Experts are calling for more oversight and personalized medical nutrition therapy from dietitians to prevent severe complications like scurvy and other micronutrient deficiencies. The controversy lies in the balance between the benefits of these drugs and the potential risks of malnutrition. Are you concerned about the potential side effects of GLP-1 drugs? What do you think about the need for more oversight and dietary guidance? Share your thoughts in the comments!
